Overall survival and long-term safety with ripretinib vs sunitinib in patients with advanced gastrointestinal stromal tumor previously treated with imatinib: Final analyses from INTRIGUE.

Authors

null

John Raymond Zalcberg

School of Public Health and Preventative Medicine, Monash University, and Alfred Health, Melbourne, Australia

John Raymond Zalcberg , Robin Lewis Jones , Jean-Yves Blay , Suzanne George , Hans Gelderblom , Patrick Schöffski , Margaret von Mehren , Yoon-Koo Kang , Albiruni Ryan Abdul Razak , Jonathan C. Trent , Steven Attia , Axel Le Cesne , Erika Davis , Haroun Achour , Matthew L. Sherman , Rodrigo Ruiz-Soto , Sebastian Bauer , Michael C. Heinrich

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2024 ASCO Gastrointestinal Cancers Symposium

Session Type

Poster Session

Session Title

Poster Session A: Cancers of the Esophagus and Stomach and Other Gastrointestinal Cancers

Track

Esophageal and Gastric Cancer,Other GI Cancer

Sub Track

Therapeutics

Clinical Trial Registration Number

NCT03673501

Citation

J Clin Oncol 42, 2024 (suppl 3; abstr 748)

DOI

10.1200/JCO.2024.42.3_suppl.748

Abstract #

748

Poster Bd #

M3

Abstract Disclosures

Similar Posters

First Author: Jonathan C. Trent

Poster

2024 ASCO Gastrointestinal Cancers Symposium

A retrospective analysis of the efficacy and safety of imatinib in elderly patients with advanced gastrointestinal stromal tumor.

A retrospective analysis of the efficacy and safety of imatinib in elderly patients with advanced gastrointestinal stromal tumor.

First Author: Takahito Awatsu